ATATcH Alternating Treatment Plans for Advanced Cancer
Alternating Treatment Plans for Participants With Advanced Thoracic/Head & Neck Cancers (ATATcH)
Rutgers, The State University of New Jersey
150 participants
Apr 28, 2022
INTERVENTIONAL
Conditions
Summary
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
It is a type of immunotherapy and works by helping your immune system to kill cancer cells
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05358548